Updated AHA/ACCF guidelines for unstable angina include newest blood-thinning drug

July 16, 2012, American Heart Association

Ticagrelor, a blood-thinning drug approved by the FDA in 2011, should be considered along with older blood thinners clopidogrel and prasugrel for treating patients who are experiencing chest pain or some heart attacks, according to joint updated guidelines issued by the American Heart Association (AHA) Task Force on Practice Guidelines and the American College of Cardiology (ACCF) Foundation.

The "focused update" on unstable angina (chest pain) or a specific kind of heart attack known as non-ST-elevation (NSTEMI) is published in Circulation: Journal of the and the .

The panel continues to recommend that all patients receive aspirin immediately after hospitalization, continuing as long as it is tolerated. Among the other new recommendations:

  • Patients unable to take aspirin may receive prasugrel for artery-opening procedures since research on the medication is restricted to those patients. Ticagrelor or may be given whether patients receive alone or are also having an ;
  • Patients undergoing invasive procedures should receive both aspirin and another antiplatelet medication;
  • Patients undergoing medical treatment only should receive aspirin indefinitely and clopidogrel or ticagrelor for up to or at least 12 months.
The AHA and ACCF issue focused updates when pivotal new data are reported that may affect changes to current recommendations and meet specific criteria. One year after the last update, the biggest change is the recommendation to consider ticagrelor as a treatment option in addition to clopidogrel and prasugrel. The panel's report highlights both the benefits (anti-clotting action) and risks (bleeding) of the new drug.

"We have put it on equal footing with two other antiplatelet medications, clopidogrel and prasugrel," said Hani Jneid, M.D., lead author of the update and an assistant professor of medicine and director of interventional cardiology research at Baylor College of Medicine, and an interventional cardiologist at the Michael E. DeBakey VA Medical Center in Houston.

occurs when the heart muscle doesn't get enough blood flow and oxygen because a coronary artery is partially blocked. In NSTEMI, there are also abnormal heart enzymes, indicating that some damage to heart muscle is already occurring.

"These conditions are very common and carry a high risk of death and recurrent heart attacks," Jneid said. "The AHA and ACCF constantly update their guidelines so that physicians can provide patients with the most appropriate, aggressive therapy with the goal of improving health and survival." To continue to improve the treatment of these important conditions, the panel encourages clinicians and hospitals to participate in a quality of care data registry designed to track and measure outcomes, complications and adherence to evidence-based recommendations.

"While this focused update of the guidelines provides important guidance to clinicians, our recommendations are not substitutes for a physician's own clinical judgments and the tailoring of therapy based on individual variability and a patient's presentation and clinical diagnosis," Jneid said.

Explore further: New study suggests potent antiplatelet drug effective with low-dose aspirin

Related Stories

New study suggests potent antiplatelet drug effective with low-dose aspirin

June 27, 2011
When taken with higher doses of aspirin (more than 300 milligrams), the experimental antiplatelet drug ticagrelor was associated with worse outcomes than the standard drug, clopidogrel, but the opposite was true with lower ...

Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events

March 26, 2012
Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall ...

One in five heart-attack deaths could be prevented with new drug

June 13, 2011
Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented ...

Recommended for you

Resolvin D-1 limits kidney damage after heart attacks

February 20, 2018
A heart attack triggers an acute inflammatory response at the damaged portion of the heart's left ventricle. If this acute inflammation lingers, it can lead to stretching of the ventricle and heart failure. The inflammation ...

Women once considered low risk for heart disease show evidence of previous heart attack scars

February 20, 2018
Women who complain about chest pain often are reassured by their doctors that there is no reason to worry because their angiograms show that the women don't have blockages in the major heart arteries, a primary cause of heart ...

Stroke drug demonstrates safety in clinical trial

February 20, 2018
A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug invented at The Scripps ...

Can your cardiac device be hacked?

February 20, 2018
Medical devices, including cardiovascular implantable electronic devices could be at risk for hacking. In a paper publishing online today in the Journal of the American College of Cardiology, the American College of Cardiology's ...

A drug long used to treat gout may help adult heart failure patients

February 20, 2018
Researchers at the University of Cincinnati (UC) College of Medicine have shown that probenecid, a drug long used to treat gout, may be able to improve heart function in adult patients who experience heart failure.

Heart attack symptoms often misinterpreted in younger women

February 20, 2018
Young women who report heart attack symptoms are more likely to have them dismissed by their providers as not heart related, a new study led by the Yale School of Public Health (YSPH) finds.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.